Conjugates of adenosine mimetics and arginine-rich peptides serve as inhibitors and fluorescent probes but not as long-lifetime photoluminescent probes for protein arginine methyltransferases.
adenosine mimetic and arginine-rich peptide conjugate
fluorescent probe
long-lifetime photoluminescence
protein arginine methyltransferase
Journal
Journal of peptide science : an official publication of the European Peptide Society
ISSN: 1099-1387
Titre abrégé: J Pept Sci
Pays: England
ID NLM: 9506309
Informations de publication
Date de publication:
Mar 2023
Mar 2023
Historique:
revised:
30
09
2022
received:
10
06
2022
accepted:
04
10
2022
pubmed:
9
10
2022
medline:
10
2
2023
entrez:
8
10
2022
Statut:
ppublish
Résumé
The conjugates of an adenosine mimetic and oligo-l-arginine or oligo-d-arginine (ARCs) were initially designed in our research group as inhibitors and photoluminescent probes targeting basophilic protein kinases. Here, we explored a panel of ARCs and their fluorescent derivatives in biochemical assays with members of the protein arginine methyltransferase (PRMT) family, focusing specifically on PRMT1. In the binding/displacement assay with detection of fluorescence anisotropy, we found that ARCs and arginine-rich peptides could serve as high-affinity ligands for PRMT1, whereas the equilibrium dissociation constant values depended dramatically on the number of arginine residues within the compounds. The fluorescently labeled probe ARC-1081 was displaced from its complex with PRMT1 by both S-adenosyl-l-methionine (SAM) and S-adenosyl-l-homocysteine (SAH), indicating binding of the adenosine mimetic of ARCs to the SAM/SAH-binding site within PRMT1. The ARCs that had previously shown microsecond-lifetime photoluminescence in complex with protein kinases did not feature such property in complex with PRMT1, demonstrating the selectivity of the time-resolved readout format. When tested against a panel of PRMT family members in single-dose inhibition experiments, a micromolar concentration of ARC-902 was required for the inhibition of PRMT1 and PRMT7. Overall, our results suggest that the compounds containing multiple arginine residues (including the well-known cell-penetrating peptides) are likely to inhibit PRMT and thus interfere with the epigenetic modification status in complex biological systems, which should be taken into consideration during interpretation of the experimental data.
Substances chimiques
Adenosine
K72T3FS567
Protein-Arginine N-Methyltransferases
EC 2.1.1.319
Fluorescent Dyes
0
Arginine
94ZLA3W45F
Peptides
0
Protein Kinases
EC 2.7.-
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e3456Subventions
Organisme : Institute of Clinical Medicine (University of Tartu, Estonia)
ID : Internal financing (PI: Jana Jaal, 2019-2022)
Organisme : Estonian Ministry of Education and Research
ID : PRG454
Organisme : Estonian Ministry of Education and Research
ID : PSG431
Informations de copyright
© 2022 European Peptide Society and John Wiley & Sons Ltd.
Références
Arrowsmith CH, Bountra C, Fish PV, Lee K, Schapira M. Epigenetic protein families: a new frontier for drug discovery. Nat Rev Drug Discov. 2012;11(5):384-400. doi:10.1038/nrd3674
Xu J, Richard S. Cellular pathways influenced by protein arginine methylation: implications for cancer. Mol Cell. 2021;81(21):4357-4368. doi:10.1016/j.molcel.2021.09.011
Hwang JW, Cho Y, Bae G-U, Kim S-N, Kim YK. Protein arginine methyltransferases: promising targets for cancer therapy. Exp Mol Med. 2021;53(5):788-808. doi:10.1038/s12276-021-00613-y
Wei H, Mundade R, Lange K, Lu T. Protein arginine methylation of non-histone proteins and its role in diseases. Cell Cycle. 2014;13(1):32-41. doi:10.4161/cc.27353
Pope AJ, Karuppiah K, Cardounel AJ. Role of the PRMT-DDAH-ADMA axis in the regulation of endothelial nitric oxide production. Pharmacol Res. 2009;60(6):461-465. doi:10.1016/j.phrs.2009.07.016
Guccione E, Richard S. The regulation, functions and clinical relevance of arginine methylation. Nat Rev Mol Cell Biol. 2019;20(10):642-657. doi:10.1038/s41580-019-0155-x
Yang Y, Bedford MT. Protein arginine methyltransferases and cancer. Nat Rev Cancer. 2013;13(1):37-50. doi:10.1038/nrc3409
Tsai W-C, Gayatri S, Reineke LC, Sbardella G, Bedford MT, Lloyd RE. Arginine demethylation of G3BP1 promotes stress granule assembly. J Biol Chem. 2016;291(43):22671-22685. doi:10.1074/jbc.M116.739573
Lee S-Y, Vuong TA, So H-K, et al. PRMT7 deficiency causes dysregulation of the HCN channels in the CA1 pyramidal cells and impairment of social behaviors. Exp Mol Med. 2020;52(4):604-614. doi:10.1038/s12276-020-0417-x
Couto E Silva A, Wu CY, Citadin CT, et al. Protein arginine methyltransferases in cardiovascular and neuronal function. Mol Neurobiol. 2020;57(3):1716-1732. doi:10.1007/s12035-019-01850-z
Blanc RS, Richard S. Arginine methylation: the coming of age. Mol Cell. 2017;65(1):8-24. doi:10.1016/j.molcel.2016.11.003
Wu Q, Schapira M, Arrowsmith CH, Barsyte-Lovejoy D. Protein arginine methylation: from enigmatic functions to therapeutic targeting. Nat Rev Drug Discov. 2021;20(7):509-530. doi:10.1038/s41573-021-00159-8
Baldwin RM, Morettin A, Côté J. Role of PRMTs in cancer: could minor isoforms be leaving a mark? World J Biol Chem. 2014;5(2):115-129. doi:10.4331/wjbc.v5.i2.115
Sohail M, Zhang M, Litchfield D, Wang L, Kung S, Xie J. Differential expression, distinct localization and opposite effect on golgi structure and cell differentiation by a novel splice variant of human PRMT5. Biochim Biophys Acta (BBA) - Mol Cell Res. 2015;1853(10):2444-2452. doi:10.1016/j.bbamcr.2015.07.003
Thiebaut C, Eve L, Poulard C, Le Romancer M. Structure, activity, and function of PRMT1. Life. 2021;11(11):1147. doi:10.3390/life11111147
Brown JI, Koopmans T, van Strien J, Martin NI, Frankel A. Kinetic analysis of PRMT1 reveals multifactorial processivity and a sequential ordered mechanism. ChemBioVhem. 2018;19(1):85-99. doi:10.1002/cbic.201700521
Eram MS, Shen Y, Szewczyk M, et al. A potent, selective and cell-active inhibitor of human type I protein arginine methyltransferases. ACS Chem Biol. 2016;11(3):772-781. doi:10.1021/acschembio.5b00839
Copeland RA. Protein methyltransferase inhibitors as precision cancer therapeutics: A decade of discovery. Phil Trans Royal Soc B: Biol Sci. 2018;373(1748):20170080. doi:10.1098/rstb.2017.0080
Ferreira de Freitas R, Ivanochko D, Schapira M. Methyltransferase inhibitors: competing with, or exploiting the bound cofactor. Molecules. 2019;24(24):4492. doi:10.3390/molecules24244492
Mann SA, DeMart MK, May B, Causey CP, Knuckley B. Histone H4-based peptoids are inhibitors of protein arginine methyltransferase 1 (PRMT1). Biochem J. 2020;477(16):2971-2980. doi:10.1042/BCJ20200534
Ragno R, Simeoni S, Castellano S, et al. Small molecule inhibitors of histone arginine methyltransferases: homology modeling, molecular docking, binding mode analysis, and biological evaluations. J Med Chem. 2007;50(6):1241-1253. doi:10.1021/jm061213n
Castellano S, Milite C, Ragno R, et al. Design, synthesis and biological evaluation of carboxy analogues of arginine methyltransferase inhibitor 1 (AMI-1). ChemMedChem. 2010;5(3):398-414. doi:10.1002/cmdc.200900459
Iannelli G, Milite C, Marechal N, et al. Turning nonselective inhibitors of type I protein arginine methyltransferases into potent and selective inhibitors of protein arginine methyltransferase 4 through a deconstruction-reconstruction and fragment-growing approach. J Med Chem. 2022;65(17):11574-11606. doi:10.1021/acs.jmedchem.2c00252
van Haren MJ, Marechal N, Troffer-Charlier N, et al. Transition state mimics are valuable mechanistic probes for structural studies with the arginine methyltransferase CARM1. Proc Natl Acad Sci U S A. 2017;114(14):3625-3630. doi:10.1073/pnas.1618401114
Zhang Y, van Haren MJ, Martin NI. Peptidic transition state analogues as PRMT inhibitors. Methods. 2020;175:24-29. doi:10.1016/j.ymeth.2019.08.003
Wang Z, Cole PA. Catalytic mechanisms and regulation of protein kinases. Methods Enzymol. 2014;548:1-21. doi:10.1016/B978-0-12-397918-6.00001-X
Lavogina D, Enkvist E, Uri A. Bisubstrate inhibitors of protein kinases: from principle to practical applications. ChemMedChem. 2010;5(1):23-34. doi:10.1002/cmdc.200900252
Enkvist E, Vaasa A, Kasari M, et al. Protein-induced long lifetime luminescence of nonmetal probes. ACS Chem Biol. 2011;6(10):1052-1062. doi:10.1021/cb200120v
Kasari M, Ligi K, Williams JAG, et al. Responsive microsecond-lifetime photoluminescent probes for analysis of protein kinases and their inhibitors. Biochim Biophys Acta (BBA) - Proteins Proteom. 2013;1834(7):1330-1335. doi:10.1016/j.bbapap.2013.02.039
Enkvist E, Lavogina D, Raidaru G, et al. Conjugation of adenosine and hexa-(D-arginine) leads to a nanomolar bisubstrate-analog inhibitor of basophilic protein kinases. J Med Chem. 2006;49(24):7150-7159. doi:10.1021/jm0605942
Kestav K, Viht K, Konovalov A, Enkvist E, Uri A, Lavogina D. Slowly on, slowly off: bisubstrate-analogue conjugates of 5-Iodotubercidin and histone H3 peptide targeting protein kinase haspin. ChemBioChem. 2017;18(8):790-798. doi:10.1002/cbic.201600697
Vaasa A, Lust M, Terrin A, Uri A, Zaccolo M. Small-molecule FRET probes for protein kinase activity monitoring in living cells. Biochem Biophys Res Commun. 2010;397(4):750-755. doi:10.1016/j.bbrc.2010.06.026
Vaasa A, Ligi K, Mohandessi S, Enkvist E, Uri A, Miller LW. Time-gated luminescence microscopy with responsive nonmetal probes for mapping activity of protein kinases in living cells. Chem Commun (Camb). 2012;48(68):8595-8597. doi:10.1039/c2cc33565d
Kriisa M, Sinijärv H, Vaasa A, et al. Inhibition of CREB phosphorylation by conjugates of adenosine analogues and arginine-rich peptides, Inhibitors of PKA Catalytic Subunit. ChemBioChem. 2015;16(2):312-319. doi:10.1002/cbic.201402526
Allolio C, Magarkar A, Jurkiewicz P, et al. Arginine-rich cell-penetrating peptides induce membrane multilamellarity and subsequently enter via formation of a fusion pore. Proc Natl Acad Sci. 2018;115(47):11923-11928. doi:10.1073/pnas.1811520115
Schmidt N, Mishra A, Lai GH, Wong GCL. Arginine-rich cell-penetrating peptides. FEBS Lett. 2010;584(9):1806-1813. doi:10.1016/j.febslet.2009.11.046
Hällbrink M, Oehlke J, Papsdorf G, Bienert M. Uptake of cell-penetrating peptides is dependent on peptide-to-cell ratio rather than on peptide concentration. Biochim Biophys Acta (BBA) - Biomembranes. 2004;1667(2):222-228. doi:10.1016/j.bbamem.2004.10.009
Patel SG, Sayers EJ, He L, et al. Cell-penetrating peptide sequence and modification dependent uptake and subcellular distribution of green florescent protein in different cell lines. Sci Rep. 2019;9(1):6298. doi:10.1038/s41598-019-42456-8
Margus H, Arukuusk P, Langel Ü, Pooga M. Characteristics of cell-penetrating peptide/nucleic acid nanoparticles. Mol Pharm. 2016;13(1):172-179. doi:10.1021/acs.molpharmaceut.5b00598
Huang Y-W, Lee H-J, Tolliver LM, Aronstam RS. Delivery of nucleic acids and nanomaterials by cell-penetrating peptides: opportunities and challenges. Biomed Res Int. 2015;2015:834079. doi:10.1155/2015/834079
Kacprzak MM, Peinado JR, Than ME, et al. Inhibition of furin by polyarginine-containing peptides: nanomolar inhibition by nona-D-arginine. J Biol Chem. 2004;279(35):36788-36794. doi:10.1074/jbc.M400484200
Osman EEA, Rehemtulla A, Neamati N. Why all the fury over furin? J Med Chem. 2022;65(4):2747-2784. doi:10.1021/acs.jmedchem.1c00518
Subramanian R, Zhu X, Hock MB, et al. Pharmacokinetics, biotransformation, and excretion of [14C]etelcalcetide (AMG 416) following a single microtracer intravenous dose in patients with chronic kidney disease on hemodialysis. Clin Pharmacokinet. 2017;56(2):179-192. doi:10.1007/s40262-016-0433-0
Manoharan G, Enkvist E, Uri A. Combining chemical and genetic approaches for development of responsive FRET-based sensor systems for protein kinases. Biophys Chem. 2016;211:39-48. doi:10.1016/j.bpc.2016.01.004
Vaasa A, Viil I, Enkvist E, et al. High-affinity bisubstrate probe for fluorescence anisotropy binding/displacement assays with protein kinases PKA and ROCK. Anal Biochem. 2009;385(1):85-93. doi:10.1016/j.ab.2008.10.030
Lavogina D, Nickl CK, Enkvist E, et al. Adenosine analogue-oligo-arginine conjugates (ARCs) serve as high-affinity inhibitors and fluorescence probes of type I CGMP-dependent protein kinase (PKGIα). Biochimica et Biophysica Acta (BBA) - Proteins Proteomics. 2010;1804(9):1857-1868. doi:10.1016/j.bbapap.2010.04.007
Lavogina D, Lust M, Viil I, et al. Structural analysis of ARC-type inhibitor (ARC-1034) binding to protein kinase A catalytic subunit and rational design of bisubstrate analogue inhibitors of basophilic protein kinases. J Med Chem. 2009;52(2):308-321. doi:10.1021/jm800797n
Lavogina D, Budu A, Enkvist E, et al. Targeting plasmodium falciparum protein kinases with adenosine analogue-oligoarginine conjugates. Exp Parasitol. 2014;138:55-62. doi:10.1016/j.exppara.2014.02.001
Kestav K, Lavogina D, Raidaru G, Chaikuad A, Knapp S, Uri A. Bisubstrate inhibitor approach for targeting mitotic kinase haspin. Bioconjug Chem. 2015;26(2):225-234. doi:10.1021/bc500464r
Lavogina D, Kalind K, Bredihhina J, et al. Conjugates of 5-isoquinolinesulfonylamides and oligo-d-arginine possess high affinity and selectivity towards rho kinase (ROCK). Bioorg Med Chem Lett. 2012;22(10):3425-3430. doi:10.1016/j.bmcl.2012.03.101
Nonga OE, Enkvist E, Herberg FW, Uri A. Inhibitors and fluorescent probes for protein kinase PKAcβ and its S54L mutant, identified in a patient with cortisol producing adenoma. Biosci Biotechnol Biochem. 2020;84(9):1839-1845. doi:10.1080/09168451.2020.1772038
Nonga OE, Lavogina D, Enkvist E, et al. Crystal structure-guided design of bisubstrate inhibitors and photoluminescent probes for protein kinases of the PIM family. Molecules. 2021;26(14):4353. doi:10.3390/molecules26144353
Ivan T, Enkvist E, Viira B, et al. Bifunctional Ligands for inhibition of tight-binding protein-protein interactions. Bioconjug Chem. 2016;27(8):1900-1910. doi:10.1021/acs.bioconjchem.6b00293
Sinijarv H, Wu S, Ivan T, Laasfeld T, Viht K, Uri A. Binding assay for characterization of protein kinase inhibitors possessing sub-picomolar to sub-millimolar affinity. Anal Biochem. 2017;531:67-77. doi:10.1016/j.ab.2017.05.017
Li W, He Y, Yang J, et al. Profiling PRMT methylome reveals roles of HnRNPA1 arginine methylation in RNA splicing and cell growth. Nat Commun. 2021;12(1):1946. doi:10.1038/s41467-021-21963-1
Bikkavilli RK, Avasarala S, Van Scoyk M, et al. In vitro methylation assay to study protein arginine methylation. J Vis Exp. 2014;92(92):51997. doi:10.3791/51997
Rinken A, Lavogina D, Kopanchuk S. Assays with detection of fluorescence anisotropy: challenges and possibilities for characterizing ligand binding to GPCRs. Trends Pharmacol Sci. 2018;39(2):187-199. doi:10.1016/j.tips.2017.10.004
Bernetti M, Masetti M, Rocchia W, Cavalli A. Kinetics of drug binding and residence time. Annu Rev Phys Chem. 2019;70(1):143-171. doi:10.1146/annurev-physchem-042018-052340
Pflug A, Rogozina J, Lavogina D, et al. Diversity of bisubstrate binding modes of adenosine analogue-oligoarginine conjugates in protein kinase a and implications for protein substrate interactions. J Mol Biol. 2010;403(1):66-77. doi:10.1016/j.jmb.2010.08.028
Ekambaram R, Manoharan G, Enkvist E, Ligi K, Knapp S, Uri A. PIM kinase-responsive microsecond-lifetime photoluminescent probes based on selenium-containing heteroaromatic tricycle. RSC Adv. 2015;5(117):96750-96757. doi:10.1039/C5RA20777K
Tewary SK, Zheng YG, Ho M-C. Protein arginine methyltransferases: insights into the enzyme structure and mechanism at the atomic level. Cell Mol Life Sci. 2019;76(15):2917-2932. doi:10.1007/s00018-019-03145-x
Roskoski R. Properties of FDA-approved small molecule protein kinase inhibitors. Pharmacol Res. 2019;144:19-50. doi:10.1016/j.phrs.2019.03.006
Attwood MM, Fabbro D, Sokolov AV, Knapp S, Schiöth HB. Trends in kinase drug discovery: targets, indications and inhibitor design. Nat Rev Drug Discov. 2021;20(11):839-861. doi:10.1038/s41573-021-00252-y
Zhou R, Xie Y, Hu H, et al. Molecular mechanism underlying PRMT1 dimerization for SAM binding and methylase activity. J Chem Inf Model. 2015;55(12):2623-2632. doi:10.1021/acs.jcim.5b00454
Zhang X, Cheng X. Structure of the predominant protein arginine methyltransferase PRMT1 and analysis of its binding to substrate peptides. Structure. 2003;11(5):509-520. doi:10.1016/S0969-2126(03)00071-6
Hasegawa M, Toma-Fukai S, Kim J-D, Fukamizu A, Shimizu T. Protein arginine methyltransferase 7 has a novel homodimer-like structure formed by tandem repeats. FEBS Lett. 2014;588(10):1942-1948. doi:10.1016/j.febslet.2014.03.053
Hu H, Luo C, Zheng YG. Transient kinetics define a complete kinetic model for protein arginine methyltransferase 1. J Biol Chem. 2016;291(52):26722-26738. doi:10.1074/jbc.M116.757625
Wang C, Zhu Y, Chen J, et al. Crystal structure of arginine methyltransferase 6 from Trypanosoma brucei. PLoS ONE. 2014;9(2):e87267. doi:10.1371/journal.pone.0087267
Tang J, Frankel A, Cook RJ, et al. PRMT1 is the predominant type I protein arginine methyltransferase in mammalian cells. J Biol Chem. 2000;275(11):7723-7730. doi:10.1074/jbc.275.11.7723
Rahnel H, Viht K, Lavogina D, et al. A selective biligand inhibitor of CK2 increases caspase-3 activity in cancer cells and inhibits platelet aggregation. ChemMedChem. 2017;12(20):1723-1736. doi:10.1002/cmdc.201700457
Martin RM, Ter-Avetisyan G, Herce HD, Ludwig AK, Lättig-Tünnemann G, Cardoso MC. Principles of protein targeting to the nucleolus. Nucleus. 2015;6(4):314-325. doi:10.1080/19491034.2015.1079680
Wang H, Feng Z, Tan W, Xu B. Assemblies of D-peptides for targeting cell nucleolus. Bioconjug Chem. 2019;30(10):2528-2532. doi:10.1021/acs.bioconjchem.9b00524
Ekokoski E, Aitio O, Törnquist K, Yli-Kauhaluoma J, Tuominen RK. HIV-1 tat-peptide inhibits protein kinase C and protein kinase A through substrate competition. Eur J Pharm Sci. 2010;40(5):404-411. doi:10.1016/j.ejps.2010.04.013
Kurnaeva MA, Sheval EV, Musinova YR, Vassetzky YS. Tat basic domain: A “Swiss Army knife” of HIV-1 tat? Rev Med Virol. 2019;29(2):e2031 doi:10.1002/rmv.2031
Lee D, Pacheco S, Liu M. Biological effects of tat cell-penetrating peptide: A multifunctional Trojan horse? Nanomedicine. 2014;9(1):5-7. doi:10.2217/nnm.13.193